Safety and Performance Study of the CAdiscTM-L Lumbar Spinal Disc Replacement Device For CE Marking (DISCERN)

This study has been completed.
Sponsor:
Information provided by:
Ranier Technology Limited
ClinicalTrials.gov Identifier:
NCT00949936
First received: July 30, 2009
Last updated: October 14, 2010
Last verified: October 2010

July 30, 2009
October 14, 2010
October 2009
Not Provided
Improvement of 15 points on the Oswestry Disability Index (ODI) scale at 3 months post-surgery, compared to baseline
Same as current
Complete list of historical versions of study NCT00949936 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety and Performance Study of the CAdiscTM-L Lumbar Spinal Disc Replacement Device For CE Marking
Debilitating Low Back paIn: Multi-centre Safety and performanCe invEstigation Of CAdiscTM-L, Total Disc ReplacemeNt Therapy

The purpose of this European Union (EU) study to evaluate the safety and performance of the CAdiscTM-L Lumbar Spinal Disc Replacement Device in the surgical replacement of the lumbar intervertebral discs (L3 to S1) for patients requiring surgical intervention for total lumbar disc replacement for the treatment of debilitating, chronic low back pain.

Study Design: International, multicenter, open, clinical investigation with comparison to pre-operative

Currently there are two surgical procedures for the treatment of chronic low back pain: Spinal fusion and Total Disc Replacement. CAdisc™-L(Compliant Artificial disc - Lumbar) is a Lumbar total disc replacement product that preserves motion and restores disc height and stability

Surgical access is via a routine anterior approach with discectomy (removal of the diseased disc), which is performed prior to implantation of the CAdisc™-L. Instruments are then used to prepare the disc space and to controllably place the replacement disc at the target point. It is not intended for the surgery to differ in type, duration or risk to any other device of this nature.

Interventional
Not Provided
Primary Purpose: Treatment
  • Chronic Low Back Pain
  • Lumbar Degenerative Disc Disease
Device: CAdisc™-L (Total Disc Replacement)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
June 2010
Not Provided

Inclusion Criteria:

  • Male or non pregnant, non-lactating female
  • Aged between 25-65 years (inclusive)
  • BMI < 35
  • Preoperative ODI > 30 points
  • Chronic low back pain, and is in the opinion of the investigator a suitable candidate for anterior lumbar surgery
  • Completed at least 6 months of conservative treatment without obtaining adequate symptomatic relief
  • Degenerative disc changes at a single level between L3 - L4, or L4 - L5, or L5 - S1 as confirmed by positive discography and visualized by X-Ray, CT or MRI scan and/or with one or more of the following:

    • Decrease in disc height < 50% (or up to 80% and no benefit from facet injections)
    • Annular thickening
    • Herniated nucleus pulpous
  • Subject is able to give voluntary, written informed consent to participate in this investigation and from whom written consent must be obtained prior to enrolment.

Exclusion Criteria:

  • Back or leg pain of unknown aetiology
  • Radicular or sciatic pain which is more severe than low back pain
  • Previous lumbar spinal surgery which could affect the trial outcome (e.g., disc replacement)
  • Obvious signs of psychological or worker's compensation or litigation claim elements to their condition, or are actively engaged in such activities
  • Subject is unwilling or unable to give consent or adhere to the follow-up programme
  • Active infection or metastatic disease
  • Non-degenerative spondylolisthesis
  • Degenerative spondylolisthesis > grade 1
  • Known allergy to any of the implant materials
  • Osteoporosis (if suspected to be confirmed by bone density being 2.5SD below normal as assessed using DEXA analysis in post-menopausal females if suggested by X-ray or other risk factors)
  • Osteopenia
  • Bony lumbar stenosis
  • Pars defect
  • Isolated radicular compression syndromes, especially due to disc herniation
  • Clinically compromised vertebral bodies at the affected levels due to current or past trauma
  • Subject is skeletally immature as determined by the investigator
  • Subject has participated in another clinical investigation or study with an investigational medical device within the last 60 days
  • Concomitant medications that are known significantly to interfere with bone/soft tissue healing, e.g. steroids.
  • Uncorrected iliac, aorto-iliac, or aortic aneurysm disease.
  • Spinal instability (> 3mm translation or > 5° angulation) confirmed by functional radiological assessment.
  • Degenerative disc changes at the L6 - S1 level
Both
25 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Germany,   Netherlands,   United Kingdom
 
NCT00949936
Ranier01/2008
No
Ian Quirk : Worldwide Clinical & Regulatory Affairs Director, Ranier Technology Ltd
Ranier Technology Limited
Not Provided
Not Provided
Ranier Technology Limited
October 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP